Miami-based company partners with Pfizer to develop new growth hormone drug
Pfizer's business development team finds promise in OPKO Health developing growth-hormone deficiency drug
MIAMI – OPKO Health was set to get an upfront payment of $295 million and could get $275 million more from Pfizer to develop a new drug, the company announced Monday.
Pfizer's business development team made a deal with billionaire Philip Frost's OPKO Health, based in Miami, 4400 Biscayne Blvd.
The pharmaceutical and diagnostics company is developing a "long-acting hGH-CTP," a growth-hormone deficiency treatment that would require weekly injections instead of the current standard of daily injections.
After the upfront payment, the company is also eligible to receive an additional $275 million if it reaches certain regulatory milestones, the press release said. In turn, Pfizer gets a exclusive license to commercialize the drug worldwide.
The announcement of the partnership with Pfizer sent OPKO Health stocks up 13 percent before the market opened, Market Watch reported. By 4 p.m. the stock was up 8.7 percent.
The drug is in a global phase 3 trial in adults and a global phase 2 trial in children and has orphan drug designation in the U.S. and Europe for both adults and children.
Copyright 2014 by Local10.com. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.